These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32612262)

  • 1. Leveraging preclinical models for the development of Alzheimer disease therapeutics.
    Scearce-Levie K; Sanchez PE; Lewcock JW
    Nat Rev Drug Discov; 2020 Jul; 19(7):447-462. PubMed ID: 32612262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
    Lanoiselée HM; Nicolas G; Wallon D; Rovelet-Lecrux A; Lacour M; Rousseau S; Richard AC; Pasquier F; Rollin-Sillaire A; Martinaud O; Quillard-Muraine M; de la Sayette V; Boutoleau-Bretonniere C; Etcharry-Bouyx F; Chauviré V; Sarazin M; le Ber I; Epelbaum S; Jonveaux T; Rouaud O; Ceccaldi M; Félician O; Godefroy O; Formaglio M; Croisile B; Auriacombe S; Chamard L; Vincent JL; Sauvée M; Marelli-Tosi C; Gabelle A; Ozsancak C; Pariente J; Paquet C; Hannequin D; Campion D;
    PLoS Med; 2017 Mar; 14(3):e1002270. PubMed ID: 28350801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
    Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
    J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.
    Bertram L; Tanzi RE
    Nat Rev Neurosci; 2008 Oct; 9(10):768-78. PubMed ID: 18802446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics.
    Hussain I
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):395-402. PubMed ID: 20522015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Emerging Therapeutic Targets Revealed by Genome Analysis in Alzheimer's Disease].
    Ikeuchi T
    Brain Nerve; 2017 Jul; 69(7):789-798. PubMed ID: 28739993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rodent models for Alzheimer's disease drug discovery.
    Puzzo D; Gulisano W; Palmeri A; Arancio O
    Expert Opin Drug Discov; 2015 Jul; 10(7):703-11. PubMed ID: 25927677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.
    Hung A; Schneider M; Lopez MH; McClellan M
    J Manag Care Spec Pharm; 2020 Jul; 26(7):888-900. PubMed ID: 32584672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches.
    Van Broeck B; Van Broeckhoven C; Kumar-Singh S
    Neurodegener Dis; 2007; 4(5):349-65. PubMed ID: 17622778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genes in Alzheimer's disease].
    Hoenicka J
    Rev Neurol; 2006 Mar 1-15; 42(5):302-5. PubMed ID: 16538594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.
    Haure-Mirande JV; Audrain M; Fanutza T; Kim SH; Klein WL; Glabe C; Readhead B; Dudley JT; Blitzer RD; Wang M; Zhang B; Schadt EE; Gandy S; Ehrlich ME
    Acta Neuropathol; 2017 Nov; 134(5):769-788. PubMed ID: 28612290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metal and inflammatory targets for Alzheimer's disease.
    Rogers JT; Lahiri DK
    Curr Drug Targets; 2004 Aug; 5(6):535-51. PubMed ID: 15270200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of Alzheimer disease: back to the future.
    Bertram L; Lill CM; Tanzi RE
    Neuron; 2010 Oct; 68(2):270-81. PubMed ID: 20955934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
    Chabrier PE
    Ann Pharm Fr; 2009 Mar; 67(2):97-103. PubMed ID: 19298893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered tissues and strategies to overcome challenges in drug development.
    Khalil AS; Jaenisch R; Mooney DJ
    Adv Drug Deliv Rev; 2020; 158():116-139. PubMed ID: 32987094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression.
    Teipel SJ; Buchert R; Thome J; Hampel H; Pahnke J
    Prog Neurobiol; 2011 Dec; 95(4):547-56. PubMed ID: 21601614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seizures in Alzheimer's disease.
    Born HA
    Neuroscience; 2015 Feb; 286():251-63. PubMed ID: 25484360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?
    Deming Y; Li Z; Benitez BA; Cruchaga C
    Expert Opin Ther Targets; 2018 Jul; 22(7):587-598. PubMed ID: 29889572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APP mouse models for Alzheimer's disease preclinical studies.
    Sasaguri H; Nilsson P; Hashimoto S; Nagata K; Saito T; De Strooper B; Hardy J; Vassar R; Winblad B; Saido TC
    EMBO J; 2017 Sep; 36(17):2473-2487. PubMed ID: 28768718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.